Shares of Immunomedics, Inc. (NASDAQ:IMMU) ended Friday session in green amid volatile trading. The shares closed up +0.06 points or 2.24% at $2.74 with 544,718.00 shares getting traded. Post opening the session at $2.72, the shares hit an intraday low of $2.66 and an intraday high of $2.76 and the price vacillated in this range throughout the day. The company has a market cap of $254.14 million and the numbers of outstanding shares have been calculated to be 95.87 million shares.
Immunomedics, Inc. (IMMU) announced that it will present at three upcoming investor conferences:
Credit Suisse 2016 Antibody Day at 8:00 a.m. Eastern Time on Wednesday, September 7, 2016 at Credit Suisse’s campus in New York City;
2016 Wells Fargo Healthcare Conference at 3:30 pm Eastern Time on Thursday, September 8, 2016 at the Westin Waterfront in Boston, MA; and
Rodman & Renshaw 18th Annual Global Investment Conference at 4:15 pm on Tuesday, September 13, 2016 at the Lotte New York Palace Hotel in New York City.
The Company will also participate in one-on-one meetings with institutional investors at these conferences.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended Friday session in red amid volatile trading. The shares closed down -0.51 points or -1.59% at $31.59 with 1.53 million shares getting traded. Post opening the session at $32.20, the shares hit an intraday low of $31.02 and an intraday high of $32.40 and the price vacillated in this range throughout the day. The company has a market cap of $3.78 billion and the numbers of outstanding shares have been calculated to be 119.75 million shares.
On August 24, 2016 ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer, effective August 22, 2016. Mr. Young reports to Steve Davis, ACADIA’s President and Chief Executive Officer.
“Todd is a seasoned leader with significant financial and operational experience in the biopharmaceutical industry,” said Steve Davis. “His proven finance and leadership skills will be key as we bring NUPLAZID™ (pimavanserin) to patients in need, seek to maximize the significant opportunities ahead for pimavanserin, and deliver on our vision of building a leading CNS company. We welcome Todd to our team and look forward to his contributions.”
Mr. Young joins ACADIA from Baxalta Incorporated, where he served as Senior Vice President and Treasurer and played an integral role as a business leader and in creating the initial capital structure of Baxalta. Baxalta was acquired by Shire in June 2016. Prior to the acquisition, Baxalta was a global biopharmaceutical company with $6 billion in revenue that was formed in July 2015 when Baxter International Inc. spun-out its biopharmaceutical division. Prior to Baxalta, Mr. Young worked for over 14 years at Baxter holding multiple leadership roles, including Corporate Vice President and Treasurer, Vice President, International Finance, and Vice President, Global Financial Planning and Analysis (FP&A). Mr. Young’s global FP&A team was responsible for driving Baxter’s budgeting, forecasting, and long-range financial planning. As finance leader for Baxter’s international operations, he led a team of 900 finance members and helped drive business results and strategic decision making for the company’s $8 billion international commercial operations.
Early in his career, Mr. Young practiced as a tax attorney at a major law firm. Mr. Young earned his Bachelor of Arts degree in Economics from Grinnell College and his Juris Doctor from the University of Michigan School of Law.
“I am thrilled to join ACADIA,” said Todd Young. “With the recent commercial launch of NUPLAZID, the company has entered an exciting new phase. I look forward to executing on ACADIA’s growth strategy and building long-term value for shareholders.”